The potential for mergers and acquisitions in biopharma—driven by the new business-friendly tax package—is driving investor enthusiasm for biotech IPOs.
from Forbes Real Time https://www.forbes.com/sites/arleneweintraub/2018/01/30/nasdaq-exec-even-more-bullish-on-biotech-ipos-as-new-entries-soar/
via IFTTT
No comments:
Post a Comment